Any content you receive is for information purposes only. Always conduct your own research. *Sponsored
IMUNON, Inc. (Nasdaq: IMNN) Just Landed On The Top Of Our Watchlist This Morning
—Tuesday, July 21, 2026
Don’t Miss Our Next Update—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Pull Up IMNN While It’s Still Early… July 21, 2026 Dear Reader, Before the opening bell rings, we want to make sure IMUNON, Inc. (Nasdaq: IMNN) is on your screen. An independent Data Monitoring Committee recently gave the green light to IMNN to continue its late-stage Phase 3 OVATION 3 study of lead candidate IMNN-001 in newly diagnosed advanced ovarian cancer without a single modification. That is an important checkpoint for both the safety profile and the enrollment trajectory of a study designed to potentially change the standard of care in a patient population with historically limited treatment options. It is also the exact type of setup that puts a late-stage clinical name at the top of our radar. That is why IMNN is at the top of our watchlist this morning—Tuesday, July 21, 2026. But keep in mind, IMNN has less than 4M shares listed as available to the public right now. That is a very tight base for a late-stage clinical name with active analyst coverage and a Phase 3 study already dosing patients. IMNN recently made an approximate 28% move in less than a week when it went from around $1.70 on June 29 to $2.18 on July 6, according to Barchart. Four firms currently cover IMNN with bullish targets sitting well above recent levels. 
According to TipRanks, James Molloy of Alliance Global Partners reiterated a Bullish rating with a $12 target on May 12, 2026. Jason McCarthy of Maxim Group initiated Bullish coverage on April 17, 2026 with a $10 target. Emily Bodnar of H.C. Wainwright reiterated a Bullish rating with a $25 target on April 2, 2026. Rounding out the coverage, David Bautz, PhD, of Zacks Small-Cap Research published a probability-adjusted DCF valuation of $25 per share on June 5, 2026, which he stated is highly dependent on continued clinical success of the development candidates and would be adjusted based on future clinical results. The June 23 announcement was accompanied by the disclosure that IMNN remains on track to enroll 80 participants in the OVATION 3 study by the end of Q1 2027, with 27 patients already enrolled as of the Company’s most recent update. Management continues to guide enrollment completion by Q1 2029, and, importantly, the FDA has reviewed and is aligned with the Phase 3 protocol, confirming a path to a Biologics License Application filing. Add the recent $10M non-dilutive structured financing with no warrant coverage, FDA Fast Track and Orphan designations already in hand, and Phase 2 results reporting a 14.7-month median overall survival benefit, and IMNN checks the exact boxes we look for in a Phase 3 clinical name. Company Overview
IMUNON, Inc. (Nasdaq: IMNN) is a clinical-stage biotechnology company based in Lawrenceville, New Jersey, with a scientific focus on advancing therapies that recruit the body’s own biology to generate durable responses across a range of oncology and infectious disease indications. The Company builds its portfolio around a proprietary non-viralnon-vi-ral DNA technology, delivered through two distinct modalities: TheraPlas® for gene-based delivery of cytokines and other therapeutic proteins in oncology, and PLACCINE® for DNA-encoded vaccine antigens designed to elicit strong immunological responses. Together, these platforms are intended to solve for durability, delivery, and manufacturing challenges that have limited earlier generations of gene-based therapeutics. The Company’s lead clinical program is IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy for the localized treatment of newly diagnosed advanced ovarian cancer. IMNN-001 has completed the Phase 2 OVATION 2 study in 112 women and is now enrolling patients in the Phase 3 OVATION 3 registrational study. A second program, IMNN-101, is a PLACCINE-based infectious disease candidate that has completed dosing in a first-in-human study. 
IMUNON continues to develop its non-vi-ral DNA technology across these modalities and, per its published pipeline, continues to explore additional partnership pathways. A Late-Stage Oncology Focus Ovarian cancer remains one of the most challenging gynecologic malignancies to treat. According to American Cancer Society data referenced throughout the peer-reviewed literature, more than 60% of women diagnosed die within five years, and most cases are not detected until Stage III or IV when the disease has already spread outside the pelvis. The current first-line regimen has been anchored on debulking surgery combined with paclitaxel and carboplatin chemotherapy for over three decades, with meaningful survival improvements limited primarily to PARP inhibitor maintenance in the subset of patients with BRCA mutations or homologous recombination deficiency. That treatment pattern leaves a significant gap for the broader newly diagnosed advanced ovarian cancer population. It is exactly where IMNN-001 is being positioned. IL-12 is one of the most active cytokines for inducing potent anti-cancer immunity, but systemic IL-12 administration has historically produced serious toxicity. TheraPlas is designed to solve that problem by delivering the IL-12 gene locally into the tumor microenvironment via intraperitoneal infusion, generating persistent, controlled cytokine production at the tumor site rather than throughout the body. IMUNON has described its Phase 2 data as demonstrating what management referred to as an unprecedented IL-12 safety profile paired with extraordinary Phase 2 efficacy. The DNA-based cancer immunotherapy market broadly has attracted substantial capital as the sector has moved past the first wave of checkpoint inhibitors and into combination and localized approaches. Late-stage assets with orphan designation, Fast Track designation, and an aligned Phase 3 protocol are the ones most likely to command premium valuations in this space. Recent Milestones for (IMNN)
- June 23, 2026 — iDMC Recommends Phase 3 OVATION 3 Study Continue Without Modification. The independent Data Monitoring Committee recommended continuation of the Phase 3 OVATION 3 clinical trial evaluating IMNN-001 in combination with standard-of-care neoadjuvant and adjuvant chemotherapy in women with newly diagnosed advanced ovarian cancer. The Company remains on track to reach 80 enrolled participants by Q1 2027, with 27 patients already enrolled at the time of the announcement.
- June 4, 2026 — IMUNON Announces Up to $10M Cash Financing. The Company entered a uniquely structured financing that includes $2.5M of non-convertible preferred stock and $7.72M in secured promissory notes with 18-month maturities. The transaction includes no warrants and avoids the substantial discounts to market that often accompany traditional equity offerings for clinical-stage biotechnology companies.
- May 12, 2026 — IMUNON Reports First Quarter 2026 Financial Results and Business Update. The Company reported that enrollment in the Phase 3 OVATION 3 trial continues ahead of plan and confirmed that FDA has reviewed and is aligned with the Phase 3 protocol, confirming a path to BLA filing. Management reiterated that IMNN-001 is the first and only frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer.
- March 31, 2026 — IMUNON Reports 2025 Financial Results and Business Update. The Company confirmed that IMNN-001 is the first frontline immunotherapy to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with advanced ovarian cancer, and reiterated that enrollment in the Phase 3 OVATION 3 study remains ahead of plan, supported by continued interest from principal investigators and the medical community.
- March 25, 2026 — Updated Phase 2 Data Shows Continued Improvement in Median Overall Survival. Final data from the Phase 2 OVATION 2 study showed a median 14.7-month increase in overall survival (45.1 vs. 30.4 months) in women receiving IMNN-001 versus standard-of-care alone. For patients also receiving PARP inhibitor therapy, the median increase in overall survival was 24.2 months (65.6 vs. 41.4 months) compared to standard-of-care plus PARP inhibitors.
- February 5, 2026 — IMUNON Sharpens Focus on Its Phase 3 Ovarian Cancer Study. The Company announced a strategic reorganization designed to reduce operating expenses while supporting a focused strategy to rapidly advance the OVATION 3 study. The move eliminated expenses not essential to the Phase 3 trial while preserving the scientific and clinical operations necessary to execute the enrollment schedule.
7 Reasons Why (IMNN) is Topping Our Watchlist
This Morning—Tuesday, July 21, 2026… 1. Phase 3 Progress: IMNN continues advancing its Phase 3 OVATION 3 study after an independent Data Monitoring Committee recommended the trial continue without modification. 2. Small Float: IMNN has fewer than 4M shares listed as available to the public, creating a tightly held share structure. 3. Recent Momentum: According to Barchart, IMNN recently made an approximate 28% move in less than one week, climbing from around $1.70 to $2.18. 4. Analyst Coverage: IMNN is followed by four research firms, with published targets ranging from $10 to $25 and a probability-adjusted $25 DCF valuation. 5. FDA Alignment: IMNN reported that the FDA has reviewed and is aligned with its Phase 3 protocol, supporting the planned path toward a Biologics License Application filing. 6. Survival Data: IMNN reported Phase 2 results showing a 14.7-month median overall survival improvement versus standard-of-care alone in the evaluated patient population. 7. Regulatory Designations: IMNN has received both FDA Fast Track and Orphan designations while continuing enrollment in its late-stage Phase 3 clinical program.
Pull Up IMNN While It’s Still Early…
IMNN is at the top of our radar. Four firms have issued bullish targets, an independent monitoring committee has recommended that its registrational Phase 3 trial continue without modification, the FDA is aligned with the protocol and planned BLA pathway, and Phase 2 data has shown longer survival in a patient population with historically limited treatment options. Add a very tight share structure, active enrollment in the OVATION 3 study, and a recent non-dilutive financing that avoids warrant overhang, and this is exactly the type of setup we watch closely. We have all eyes on IMNN this morning. Take a look at IMNN while it’s still early. Also, keep a look out for my next update, it could be coming very shortly. Sincerely, Jeff Ackerman Managing Editor Stock News Trends |
No comments:
Post a Comment